Related Experiment Video
Updated: Jul 3, 2026
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
The Impact of Immunotherapy on Hair Repigmentation in Patients With Thoracic Tumors: A Clinical Observation Based on
Sitong Jiang1,2,3,4, Bo Li2,3,4,5, Fan Yang6
1Department of Medical Oncology, Beijing Hospital, National Center for Gerontology, Beijing, China.
Objective:
Whether hair repigmentation during cancer therapy is driven by immune checkpoint inhibitors (ICIs) or chemotherapy remains unclear. This study aimed to quantitatively identify the primary driver using a controlled design.
Methods:
In this prospective study, 29 patients with thoracic malignancies were divided into an immunotherapy group (n = 18) and a chemotherapy group (n = 11). Standardized dermoscopic images were captured before and after treatment. Hair pigmentation was quantified via grayscale analysis.
Results:
Grayscale values decreased significantly posttreatment in the immunotherapy group (p = 0.0008) but not in the chemotherapy group (p = 0.1427). The magnitude of change (ΔGrayscale) was significantly greater with immunotherapy than with chemotherapy alone (23.5 ± 24.67 vs. 4.32 ± 9.01; p = 0.0065), representing a large effect size (Cohen's d = 0.90).
Conclusion:
This controlled study provides quantitative evidence suggesting that immunotherapy, rather than chemotherapy, is closely associated with hair repigmentation. It establishes an objective methodological framework for future investigation of this phenomenon.
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...